Concepedia

Author

Suleiman Massarweh

University of Kentucky

Also Known As

Hicks, Donna J., S Massarweh, S. A. Massarweh, S. Massarweh, Suleiman A. Massarweh, Suleiman Alfred Massarweh, Suleiman Massarweh

92

Publications

4.5K

Citations

24

H-Index

36

Concepts

All Affiliations

University of KentuckyBaylor College of MedicineMarkey Cancer CenterThe University of Texas Health Science Center at San AntonioDan L Duncan Comprehensive Cancer Center
SM

About

Suleiman Massarweh is an author at University of Kentucky specializing in medicine, breast cancer, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

872

2

Cell Biology

5

5

581

3

Obstetrics

3

3

160

4

Health Sciences

2

2

148

5

Endocrinology

2

2

352

Suleiman Massarweh

×

25

Publications

4K

Citations

20

H-Index

YearCitations

Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

Jianzhong Shou, Suleiman Massarweh, C. K. Osborne,

JNCI Journal of the National Cancer Institute

2004

1.2K

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

Suleiman Massarweh, C. Kent Osborne, Chad J. Creighton,

Cancer Research

2008

491

Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance

Rachel Schiff, Suleiman Massarweh, Jiang Shou,

Clinical Cancer Research

2004

464

Crosstalk between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer

C. Kent Osborne, Jiang Shou, Suleiman Massarweh,

Clinical Cancer Research

2005

458

Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Rachel Schiff, Suleiman Massarweh, Jiang Shou,

PubMed

2003

308

Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

Grazia Arpino, Carolina Gutiérrez, Helen A. Weiss,

JNCI Journal of the National Cancer Institute

2007

189

Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor–Positive, HER-2/<i>neu</i>-Positive Breast Cancer

Suleiman Massarweh, C. Kent Osborne, Shou Jiang,

Cancer Research

2006

149

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

Chad J. Creighton, Suleiman Massarweh, Shixia Huang,

Cancer Research

2008

136

Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/<i>neu</i>-Overexpressing Breast Tumor Xenografts

Mothaffar F. Rimawi, Lisa Wiechmann, Yen-Chao Wang,

Clinical Cancer Research

2010

86

Molecular Characterization and Mortality From Breast Cancer in Men

Suleiman Massarweh, George W. Sledge, Dave P. Miller,

Journal of Clinical Oncology

2018

81

Page 1